Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aMILs with ASCT in High Risk Myeloma
NCT01858558Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2013
- Primary completion
- Jun 2019
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of marrow-infiltrating lymphocytes in multiple myeloma (MM) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Feasibility of MILs as Assessed by the Ability to Harvest, Expand, and Infuse the MILs Product at 120 days. Started Sep 2013; status: completed.
02
Drugs
marrow-infiltrating lymphocytes
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01858558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01858558.